Pages

Friday, 25 June 2021

First COVID-19 case could have emerged in China in Oct 2019 - study

 The virus that causes COVID-19 could have started spreading in China as early as October 2019 ...

June 25, 2021

Workers in PPE spray the ground with diinfectant in Baishazhou market during a visit of World Health Organization (WHO) team tasked with investigating the origins of the coronavirus (COVID-19) pandemic, in Wuhan, Hubei province, China, January 31, 2021. REUTERS/Thomas Peter

Workers in PPE spray the ground with diinfectant in Baishazhou market during a visit of World Health Organization (WHO) team tasked with investigating the origins of the coronavirus (COVID-19) pandemic, in Wuhan, Hubei province, China, January 31, 2021. REUTERS/Thomas Pete


SHANGHAI, June 25 (Reuters) - The virus that causes COVID-19 could have started spreading in China as early as October 2019, two months before the first case was identified in the central city of Wuhan, a new study showed on Friday.

Researchers from Britain's University of Kent used methods from conservation science to estimate that SARS-CoV-2 first appeared from early October to mid-November 2019, according to a paper published in the PLOS Pathogens journal.

The most likely date for the virus's emergence was Nov. 17, 2019, and it had probably already spread globally by January 2020, they estimated.

China's first official COVID-19 case was in December 2019 and was linked to Wuhan's Huanan seafood market.

However, some early cases had no known connection with Huanan, implying that SARS-CoV-2 was already circulating before it reached the market.

A joint study published by China and the World Health Organization at the end of March acknowledged there could have been sporadic human infections before the Wuhan outbreak.

In a paper released in preprintform this week, Jesse Bloom of the Fred Hutchinson Cancer Research Center in Seattle recovered deleted sequencing data from early COVID-19 cases in China.

The data showed that samples taken from the Huanan market were "not representative" of SARS-CoV-2 as a whole, and were a variant of a progenitor sequence circulating earlier, which spread to other parts of China.

The U.S. National Institutes of Health confirmed to Reuters that the samples used in the study were submitted to the Sequence Read Archive (SRA) in March 2020 and later deleted at the request of Chinese investigators, who said they would be updated and submitted to another archive.

Critics said the deletion was further evidence that China was trying to cover up the origins of COVID-19.

"Why would scientists ask international databases to delete key data that informs us about how COVID-19 began in Wuhan?" said Alina Chan, a researcher with Harvard's Broad Institute, writing on Twitter.

Another study by Australian scientists, published on Thursday in the Scientific Reports journal, used genomic data to show SARS-CoV-2 binds to human receptors far more easily than other species, suggesting it was already adapted to humans when it first emerged.

It said it was possible there was another unidentified animal with even stronger affinity that served as an intermediary species, but the hypothesis that it leaked from the lab could not be ruled out.

"While it is clear early viruses had a high propensity for human receptors, that doesn't mean they were 'man-made'," said Dominic Dwyer, infectious disease expert at Australia's Westmead Hospital who was part of the WHO team investigating COVID-19 in Wuhan this year.

"Such conclusions remain speculative," he said.

Serum samples still needed to be tested to make a stronger case about COVID-19's origins, said Stuart Turville, associate professor at the Kirby Institute, an Australian medical research organisation who was responding to the University of Kent study.

"Unfortunately with the current pressure of the lab leak hypothesis and the sensitivities in doing this follow-up research in China, it may be some time till we see reports like that," he said.

https://www.reuters.com/world/china/first-covid-19-case-could-have-hit-china-oct-2019-study-2021-06-25/

Japan to give 6 mln doses of vaccines to Taiwan, 5 SE Asia nations

 

TOKYO, June 25 (Reuters) - Japan said on Friday it would send 2 million additional doses of AstraZeneca Plc's (AZN.L) COVID-19 vaccine to Taiwan and Vietnam and arrangements were being made to send 1 million doses each to Thailand, Malaysia, Indonesia and the Philippines.



https://www.reuters.com/business/healthcare-pharmaceuticals/japan-give-1-mln-doses-vaccine-each-taiwan-vietnam-2021-06-25/

Japan to donate 1m COVID vaccine doses to Vietnam on Wednesday

 Jabs for Indonesia, Thailand, Philippines and Malaysia considered in July

Japan has secured enough AstraZeneca vaccine doses for 60 million people but does not intend to use them immediately in domestic inoculation programs.   © Reuters

TOKYO (Kyodo) -- Japan will donate 1 million coronavirus vaccine doses to Vietnam on Wednesday, Japanese Foreign Minister Toshimitsu Motegi said.

Tokyo is also mulling donating amounts of COVID-19 vaccine to Indonesia, Malaysia, the Philippines and Thailand in July, Motegi said in a news conference on Tuesday.

"After considering comprehensively the infection situation (in Vietnam), the shortage of vaccines and relationship with Japan, we have come to that decision," Motegi said.

The provision of the vaccine developed by Britain's AstraZeneca and produced under license in Japan came in response to a request from Vietnam. It follows Japan's donation of 1.24 million shots to Taiwan earlier in the month. Vietnam has been facing a resurgence of infections since April, with its health authorities reporting a hybrid coronavirus variant that combines characteristics of strains first detected in Britain and India.

While Japan has secured enough AstraZeneca vaccine doses for 60 million people and approved their use last month, it does not intend to use them immediately in public inoculation programs due to rare cases of blood clots reported overseas.


https://asia.nikkei.com/Spotlight/Coronavirus/COVID-vaccines/Japan-to-donate-1m-COVID-vaccine-doses-to-Vietnam-on-Wednesday

Sinovac-injected Indon doctors contract COVID

 Hundreds of Sinovac-injected Indonesian doctors contract COVID

Dozens hospitalized as concerns rise over efficacy against more virulent strains

A medical worker prepares a dose of the Sinovac vaccine before giving it to a doctor at a facility in Jakarta, Indonesia, on January 19, 2021.   © Reuters

JAKARTA (Reuters) -- More than 350 Indonesian doctors have contracted COVID-19 despite being vaccinated with Sinovac, and dozens have been hospitalized, officials said, as concerns rise about the efficacy of some vaccines against more virulent virus strains.

Most of the doctors were asymptomatic and self-isolating at home, said Badai Ismoyo, head of the Kudus district health office in Central Java, but dozens were in hospital with high fevers and declining oxygen saturation levels.

Kudus is battling an outbreak believed to be driven by the more transmissible Delta variant which has pushed bed occupancy rates above 90% in the district.

Designated as a priority group, Indonesian health care workers were among the first to be vaccinated when the inoculation drive started in January.

Almost all have received the COVID-19 vaccine developed by Chinese biopharmaceutical company Sinovac, according to the Indonesian Medical Association (IDI).

While the number of Indonesian health care workers dying from COVID-19 has decreased significantly -- dropping from 158 deaths this January to 13 this May, according to data initiative group LaporCOVID-19 -- public health experts say the Java hospitalizations are cause for concern.

"The data shows they have the Delta variant [in Kudus] so it is no surprise that the breakthrough infection is higher than before because as we know the majority of health care workers in Indonesia got Sinovac, and we still don't know yet how effective it is in the real world against the Delta variant," said Dicky Budiman, an epidemiologist from Australia's Griffith University.

A spokesperson from Sinovac and Indonesia's ministry of health were not immediately available for comment on the efficacy of Sinovac's CoronaVac against newer coronavirus variants.

Grappling with one of the worst outbreaks in Asia, with more than 1.9 million cases and 53,000 deaths, there has been a heavy toll on Indonesia's doctors and nurses with 946 deaths.

Many are now experiencing pandemic fatigue and taking an increasingly laissez-faire approach to health protocols after being vaccinated, said Lenny Ekawati, from LaporCOVID-19.

"That phenomenon happens quite often these days, not only within the community but also health care workers," she said, "They think because they are vaccinated that they are safe."

But as more cases of the highly transmissible Delta variant are identified in the world's fourth most populous nation, the data is starting to tell a different story.

Across Indonesia, at least five doctors and one nurse have died from COVID-19 despite being vaccinated, according to the data initiative group, although one had only received their first shot.

In Kudus, one senior doctor has died, said IDI, although it is understood he had a comorbidity.

In the Indonesian capital Jakarta, radiologist Dr Prijo Sidipratomo told Reuters he knew of at least half a dozen doctors in the city who had been hospitalized with COVID-19 in the past month despite being vaccinated, with one currently being treated in ICU.

"It is alarming for us because we cannot rely on vaccinations only," he said, urging people to strictly adhere to health protocols.

Weeks after the Muslim Eid Al-Fitr holidays, Indonesia has experienced a surge in cases, with the positivity rate exceeding 23% on Wednesday and daily cases nearing 10,000, the highest since late February.

In its latest situation report the World Health Organization called for Indonesia to implement a stricter lockdown with increased transmission due to variants of concern and a "drastic increase in bed occupancy rates" necessitating urgent action.

https://asia.nikkei.com/Spotlight/Coronavirus/COVID-vaccines/Hundreds-of-Sinovac-injected-Indonesian-doctors-contract-COVID


Blood test that finds 50 types of cancer is accurate enough to be rolled out

 Diagnostic tool being piloted by NHS England shows ‘impressive results’ in spotting tumours in early stages

 and agency

Scientists said their findings, published in the journal Annals of Oncology, show that the test accurately detects cancer often before any signs or symptoms appear, while having a very low false positive rate.

The test, developed by US-based company Grail, looks for chemical changes in fragments of genetic code – cell-free DNA (cfDNA) – that leak from tumours into the bloodstream.

The Guardian first reported on the test last year and how it had been developed using a machine learning algorithm – a type of artificial intelligence. It works by examining the DNA that is shed by tumours and found circulating in the blood. More specifically, it focuses on chemical changes to this DNA, known as methylation patterns.

Now the latest study has revealed the test has an impressively high level of accuracy. Scientists analysed the performance of the test in 2,823 people with the disease and 1,254 people without.

It correctly identified when cancer was present in 51.5% of cases, across all stages of the disease, and wrongly detected cancer in only 0.5% of cases.

In solid tumours that do not have any screening options – such as oesophageal, liver and pancreatic cancers – the ability to generate a positive test result was twice as high (65.6%) as that for solid tumours that do have screening options such as breast, bowel, cervical and prostate cancers.

Meanwhile, the overall ability to generate a positive test result in cancers of the blood, such as lymphoma and myeloma, was 55.1%.

The test correctly also identified the tissue in which the cancer was located in the body in 88.7% of cases.

Dr Eric Klein, chairman of the Glickman Urological and Kidney Institute at Cleveland Clinic in the US and first author on the research, said: “Finding cancer early, when treatment is more likely to be successful, is one of the most significant opportunities we have to reduce the burden of cancer.

“These data suggest that, if used alongside existing screening tests, the multi-cancer detection test could have a profound impact on how cancer is detected and, ultimately, on public health.”

Dr Marco Gerlinger, from the Institute of Cancer Research in London and consultant medical oncologist at the Royal Marsden NHS foundation trust, said: “This new study shows impressive results for a simple blood test that can detect multiple cancer types.

“False positives are low which is important as this will avoid misdiagnoses. For some of the most common tumour types such as bowel or lung cancer, the test even picked up cancers that were very small, at a stage where many of them could potentially be cured.

“The study was done in patients whose cancer was already diagnosed based on other tests and this screening technology still needs to be tested in actual screening trials before routine use.

“But it already allows a glance at early cancer detection in the future which will almost certainly be built around liquid biopsy tests, which detect cancer DNA in the bloodstream.”

Meanwhile, the results of the NHS pilot of the test, which will include 140,000 participants, are expected by 2023.

Prof Peter Johnson, national NHS clinical director for cancer, said: “This latest study provides further evidence that blood tests like this could help the NHS meet its ambitious target of finding three-quarters of cancers at an early stage, when they have the highest chance of cure.

“The data is encouraging and we are working with Grail on studies to see how this test will perform in clinics across the NHS, which will be starting very soon.”

https://www.theguardian.com/society/2021/jun/25/blood-test-that-finds-50-types-of-cancer-is-accurate-enough-to-be-rolled-out

Do you sleep for less than 7.5 hours? Watch this - Gravitas Plus

 Premiered on 6 Feb 2021

2.91M subscribers
SUBSCRIBE

Are you sleeping less than 7.5 hours a night? Your life could be at risk. Studies show sleep deprivation increases the risk of cancer. Sleeping less also makes you a bad worker and takes a toll on your pocket.

https://www.youtube.com/watch?v=MgI1AxIvyMw

Chinese vaccines are facing global scrutiny 11 Jun 21 Gravitas

 11 Jun 2021

2.91M subscribers
SUBSCRIBE
Chinese vaccines are facing global scrutiny. From Mongolia to Bahrain to Seychelles, questions are being asked on the effectiveness of Made In China shots. How safe are they really? WION’s Palki Sharma gets you a report. #ChineseVaccines #COVID #WorldNews

https://www.youtube.com/watch?v=GzcyVVElz5o

5 Jun 21 Gravitas Plus: The Lab Leak Theory


Premiered on 5 Jun 2021

2.91M subscribers
SUBSCRIBE
18 months & 3.7 million deaths later, the Lab Leak Theory is being taken seriously. Is there new evidence now? Why did the world wait so long? Why were our reports labelled “fake” & “misleading?” On Gravitas Plus, WION's Palki Sharma decodes the politics & possibility of a Made In China virus. #GravitasPlus #LabLeakTheory #MadeInChina About Channel: WION -The World is One News, examines global issues with in-depth analysis. We provide much more than the news of the day. Our aim to empower people to explore their world. With our Global headquarters in New Delhi, we bring you news on the hour, by the hour. We deliver information that is not biased. We are journalists who are neutral to the core and non-partisan when it comes to the politics of the world. People are tired of biased reportage and we stand for a globalised united world. So for us the World is truly One.